Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure

Autor: Adriaan A. Voors, Hans L. Hillege, Wouter Ouwerkerk, Marco Metra, Gerjan Navis, Peter van der Meer, Aeilko H. Zwinderman, Gerasimos Filippatos, Nilesh J. Samani, Piotr Ponikowski, Pim van der Harst, Chim C. Lang, Dirk J. van Veldhuisen, Stefan D. Anker, Martin H. de Borst, Kevin Damman, Leong L. Ng, Jozine M. ter Maaten, John G.F. Cleland, Kenneth Dickstein, Faiez Zannad
Přispěvatelé: Graduate School, Epidemiology and Data Science, Dermatology, APH - Methodology, Cardiovascular Centre (CVC), Life Course Epidemiology (LCE), Groningen Kidney Center (GKC), Lifestyle Medicine (LM), Value, Affordability and Sustainability (VALUE), Groningen Institute for Organ Transplantation (GIOT), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE)
Rok vydání: 2018
Předmět:
Male
CHRONIC KIDNEY-DISEASE
Fibroblast growth factor 23
Angiotensin receptor
Internationality
030232 urology & nephrology
Volume overload
030204 cardiovascular system & hematology
urologic and male genital diseases
Left ventricular hypertrophy
FGF23
Heart failure
Prognosis
Cardiology and Cardiovascular Medicine
ANGIOTENSIN-ALDOSTERONE SYSTEM
0302 clinical medicine
Prospective Studies
CONVERTING ENZYME-INHIBITION
Aged
80 and over
ASSOCIATION HFA
Hazard ratio
Middle Aged
EUROPEAN-SOCIETY
3. Good health
Hospitalization
Treatment Outcome
Disease Progression
Cardiology
Female
medicine.medical_specialty
Renal function
1102 Cardiovascular Medicine And Haematology
03 medical and health sciences
LEFT-VENTRICULAR HYPERTROPHY
Internal medicine
medicine
Humans
cardiovascular diseases
CARDIOVASCULAR EVENTS
Aged
Proportional hazards model
business.industry
MORTALITY
Stroke Volume
medicine.disease
R1
Fibroblast Growth Factors
Fibroblast Growth Factor-23
stomatognathic diseases
Cardiovascular System & Hematology
business
Biomarkers
Follow-Up Studies
TASK-FORCE
Zdroj: International journal of cardiology, 253, 84-90. Elsevier Ireland Ltd
International Journal of Cardiology, 253, 84-90. ELSEVIER IRELAND LTD
ISSN: 0167-5273
DOI: 10.1016/j.ijcard.2017.10.010
Popis: Background: Fibroblast growth factor (FGF) 23 is a hormone that increases urinary phosphate excretion and regulates renal sodium reabsorption and plasma volume. We studied the role of plasma FGF23 in therapy optimization and outcomes in patients with new-onset and worsening heart failure (HF).Methods: We measured plasma C-terminal FGF23 levels at baseline in 2399 of the 2516 patients included in the BIOlogy Study to Tailored Treatment in Chronic HF (BIOSTAT-CHF) trial. The association between FGF23 and outcome was evaluated by Cox regression analysis adjusted for potential confounders.Results: Median FGF23 was 218.0 [IQR: 117.1-579.3] RU/ml; patients with higher FGF23 levels had a worse NYHA class, more signs of congestion, and were less likely to use an ACE-inhibitor (ACEi) or angiotensin receptor blocker (ARBs) at baseline (all P Conclusions: In patients with new-onset and worsening HF, higher plasma FGF23 levels were independently associated with volume overload, less successful uptitration of ACEi/ARBs and an increased risk of all-cause mortality and HF hospitalization. (c) 2017 Elsevier B.V. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: